News

Ebru Demir, MSc, PhD: Exploring the brain’s blueprint for connection

SIU research scientist Ebru Demir studies how the brain forms, values and remembers human relationships — and what happens when that process breaks down.
News

Ebru Demir, MSc, PhD: Exploring the brain’s blueprint for connection

SIU research scientist Ebru Demir studies how the brain forms, values and remembers human relationships — and what happens when that process breaks down.
News

Ebru Demir, MSc, PhD: Exploring the brain’s blueprint for connection

SIU research scientist Ebru Demir studies how the brain forms, values and remembers human relationships — and what happens when that process breaks down.
News

Ebru Demir, MSc, PhD: Exploring the brain’s blueprint for connection

SIU research scientist Ebru Demir studies how the brain forms, values and remembers human relationships — and what happens when that process breaks down.
Trial
Psychiatry

ITI-007-601: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Lumateperone in the Treatment of Irritability Associated with Autism Spectrum Disorder in Pediatric Patients 5 to 17 Years of Age

Active recruiting
The primary objective is to evaluate the efficacy of high and low doses of lumateperone vs placebo for the treatment of irritability associated with autism spectrum disorder (ASD) in pediatric patients as measured by the change from baseline to end of Week 6 in the ABC Irritability (ABC-I) subscale score.
Contact: Oladele Owasoyo 217-545-7231
Trial
Neurology

Xenon XPF-010-303: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Active recruiting
The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.
Contact: Stephanie Kohlrus 217-545-3013
Trial
Neurology

Xenon XPF-010-302: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Active recruiting
The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.
Contact: Stephanie Kohlrus 217-545-3013
Trial
Neurology

UCB EP0165: An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting
The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazolam.
Contact: Rylee Manka 217-545-1394
Trial
Neurology

UCB EP0162: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting
The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.
Contact: Rylee Manka 217-545-1394
Trial
Neurology

Supernus Renaissance 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures

Active recruiting

To evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.

Contact: Stephanie Kohlrus 217-545-3013
Subscribe to Patient